Trials / Completed
CompletedNCT00002041
Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
To determine the appropriate duration of amphotericin B therapy for Candida esophagitis. To compare the effectiveness of two different amphotericin B doses in the treatment of biopsy-proven Candida esophagitis. To determine if low-dose amphotericin B is less toxic than standard dose therapy during a limited treatment period. To evaluate pharmacokinetic and pharmacodynamic parameters of the two different dosing regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amphotericin B |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2007-10-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00002041. Inclusion in this directory is not an endorsement.